| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Improved survival with ipilimumab in patients with metastatic melanoma.
|
N Engl J Med
|
2010
|
67.34
|
|
2
|
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
|
N Engl J Med
|
2012
|
52.99
|
|
3
|
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
|
N Engl J Med
|
2011
|
45.46
|
|
4
|
Inhibition of mutated, activated BRAF in metastatic melanoma.
|
N Engl J Med
|
2010
|
36.57
|
|
5
|
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
|
Nature
|
2010
|
18.69
|
|
6
|
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
|
Nature
|
2010
|
16.12
|
|
7
|
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2009
|
13.52
|
|
8
|
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
|
N Engl J Med
|
2015
|
12.74
|
|
9
|
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
|
Cancer Cell
|
2010
|
12.50
|
|
10
|
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
|
Nature
|
2011
|
10.77
|
|
11
|
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
|
J Clin Oncol
|
2014
|
9.86
|
|
12
|
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
|
N Engl J Med
|
2012
|
6.93
|
|
13
|
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.
|
Nat Commun
|
2012
|
4.94
|
|
14
|
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2005
|
4.64
|
|
15
|
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
|
J Clin Oncol
|
2008
|
3.58
|
|
16
|
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
|
J Clin Oncol
|
2008
|
3.00
|
|
17
|
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
|
J Clin Oncol
|
2009
|
2.97
|
|
18
|
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
|
J Clin Oncol
|
2011
|
2.87
|
|
19
|
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
|
J Clin Oncol
|
2013
|
2.51
|
|
20
|
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
|
Cancer Discov
|
2012
|
2.48
|
|
21
|
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
|
J Clin Oncol
|
2012
|
2.45
|
|
22
|
Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses.
|
Clin Cancer Res
|
2007
|
2.28
|
|
23
|
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.
|
Cancer Discov
|
2012
|
2.27
|
|
24
|
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.
|
J Clin Oncol
|
2012
|
2.21
|
|
25
|
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
|
J Clin Oncol
|
2008
|
2.09
|
|
26
|
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
|
J Clin Oncol
|
2005
|
2.07
|
|
27
|
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
|
Cancer
|
2006
|
1.75
|
|
28
|
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
|
Clin Cancer Res
|
2013
|
1.66
|
|
29
|
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
|
Cancer
|
2012
|
1.54
|
|
30
|
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
|
Cancer Res
|
2004
|
1.51
|
|
31
|
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
|
J Clin Oncol
|
2003
|
1.49
|
|
32
|
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
|
J Immunother
|
2013
|
1.48
|
|
33
|
Sunlight and reduced risk of cancer: is the real story vitamin D?
|
J Natl Cancer Inst
|
2005
|
1.37
|
|
34
|
Retracted
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
|
BJU Int
|
2005
|
1.18
|
|
35
|
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.
|
J Clin Oncol
|
2002
|
1.15
|
|
36
|
RAF265 inhibits the growth of advanced human melanoma tumors.
|
Clin Cancer Res
|
2012
|
1.09
|
|
37
|
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
|
Clin Cancer Res
|
2007
|
1.07
|
|
38
|
Update on the targeted therapy of melanoma.
|
Curr Treat Options Oncol
|
2013
|
1.06
|
|
39
|
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.
|
Cancer
|
2009
|
1.04
|
|
40
|
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
|
Clin Cancer Res
|
2012
|
1.04
|
|
41
|
Beyond histology: translating tumor genotypes into clinically effective targeted therapies.
|
Clin Cancer Res
|
2014
|
1.01
|
|
42
|
Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431).
|
Clin Cancer Res
|
2008
|
1.01
|
|
43
|
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
|
Clin Cancer Res
|
2009
|
0.98
|
|
44
|
B-RAF inhibitors: an evolving role in the therapy of malignant melanoma.
|
Curr Oncol Rep
|
2010
|
0.97
|
|
45
|
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.
|
J Immunother
|
2009
|
0.93
|
|
46
|
Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer.
|
Cancer Immunol Immunother
|
2002
|
0.92
|
|
47
|
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
|
Cancer
|
2008
|
0.92
|
|
48
|
Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
|
Cancer Immunol Immunother
|
2005
|
0.92
|
|
49
|
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
|
Clin Genitourin Cancer
|
2007
|
0.89
|
|
50
|
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
|
Clin Cancer Res
|
2002
|
0.89
|
|
51
|
Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.
|
AJR Am J Roentgenol
|
2013
|
0.86
|
|
52
|
Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
|
Semin Cancer Biol
|
2003
|
0.86
|
|
53
|
Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer.
|
Clin Cancer Res
|
2004
|
0.84
|
|
54
|
Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.
|
Histopathology
|
2013
|
0.84
|
|
55
|
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
|
Cancer
|
2010
|
0.81
|
|
56
|
Biological drug duo delivers one-two tumor punch.
|
Nat Med
|
2003
|
0.79
|
|
57
|
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.
|
Invest New Drugs
|
2011
|
0.78
|
|
58
|
When will melanoma vaccines be proven effective?
|
J Clin Oncol
|
2003
|
0.78
|
|
59
|
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
|
Cell
|
2017
|
0.78
|
|
60
|
Trametinib in the treatment of melanoma.
|
Expert Opin Biol Ther
|
2015
|
0.76
|
|
61
|
Spindle cell squamous carcinoma during BRAF inhibitor therapy for advanced melanoma: an aggressive secondary neoplasm of undetermined biologic potential.
|
JAMA Dermatol
|
2014
|
0.76
|
|
62
|
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
|
J Immunother
|
2017
|
0.76
|
|
63
|
Combination Immunotherapy: An Emerging Paradigm in Cancer Therapeutics.
|
Oncology (Williston Park)
|
2015
|
0.76
|
|
64
|
Oral health in oncology: impact of immunotherapy.
|
Support Care Cancer
|
2014
|
0.75
|
|
65
|
BRAFV600E-mutant melanoma presenting with cardiac involvement.
|
J Natl Compr Canc Netw
|
2014
|
0.75
|
|
66
|
Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
|
Clin Cancer Res
|
2006
|
0.75
|
|
67
|
Novel Targeted Therapies for Metastatic Melanoma.
|
Cancer J
|
2017
|
0.75
|
|
68
|
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
|
J Immunother
|
2007
|
0.75
|
|
69
|
Targeting multiple genetic aberrations in isolated tumor cells by spectral fluorescence in situ hybridization.
|
Cancer Detect Prev
|
2002
|
0.75
|